Clinical Trials Logo

Filter by:
NCT ID: NCT04087993 Suspended - Clinical trials for Iron Deficiency Anemia

Polyglucoferron Compared to i.v. Ferric Carboxymaltose and Oral Iron Substitution in Preoperative Treatment of Iron Deficiency Anaemia in Patients

IDA-I
Start date: May 15, 2020
Phase: Phase 3
Study type: Interventional

Patients with IDA and for whom fast replenishment of iron stores is necessary, e.g. if its not appropriated to postpone surgery, will be identified within 28 to 42 days before surgery. Patients will be randomised to receive either Polyglucoferron intravenously (i.v.), Ferric Carboxymaltose i.v. or oral iron substitution with Ferrous sulfate.

NCT ID: NCT04084431 Suspended - Brain Metastases Clinical Trials

Supportive Care With or Without Repeated Whole Brain Radiotherapy in Patients With Recurrent Brain Metastases

RECARE
Start date: July 1, 2019
Phase: N/A
Study type: Interventional

Patients with solid cancers may develop cerebral metastases, requiring whole brain radiotherapy (WBRT). Furthermore, in several cases, a secondary course of WBRT might be required due to intracerebral recurrence and limited options for alternative treatments, besides optimal supportive care (OSC). There have been few reports on re-irradiation of the whole brain, but further evaluation especially of the optimal dose concept is warranted. Especially, the efficacy compared to OSC has to date not been evaluated. The present trial aims at evaluating the efficacy of a repeated WBRT with a total dose of 20 Gy in 10 fractions compared to OSC. Primary endpoint is time to WHO performance status (PS) deterioration to more than 3 (duration of functional independence). Secondary endpoints are quality of life, overall survival, radiation-induced toxicity and functional independence assessed by the Barthel Index of Activities of Daily Living (ADL)1.

NCT ID: NCT04042116 Suspended - Clinical trials for Advanced Solid Tumor

A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor

Start date: July 29, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, Phase 1b/2 study to determine the recommended dose of lucitanib in combination with nivolumab in patients with an advanced solid tumor (Phase 1b); followed by evaluation of the safety and efficacy of lucitanib and nivolumab in patients with an advanced gynecological solid tumor (Phase 2) and evaluate the effects of dosing under fasting or fed state (Food Effect)

NCT ID: NCT03737448 Suspended - Clinical trials for Acute-On-Chronic Liver Failure

TRimetazidine for acUte on Chronic Liver Failure STudy

TRUST
Start date: November 28, 2018
Phase: Phase 1
Study type: Interventional

The study will assess the pharmacokinetics (PK), tolerability, and safety of oral trimetazidine administered to subjects with AD (ACLF Grade 0) or with ACLF Grade 1 or 2.

NCT ID: NCT03358706 Suspended - Ulcerative Colitis Clinical Trials

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

Start date: February 2, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the potential effects of an intravenous (IV) induction and subcutaneous (SC) maintenance administration of ustekinumab on the pharmacokinetic (PK) of a cocktail of representative probe substrates of cytochrome P450 (CYP) enzymes (CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2) in participants with Active Crohn's disease (CD) or Ulcerative Colitis (UC).

NCT ID: NCT03299764 Suspended - COPD Clinical Trials

Evaluation of Non-invasive Pursed-lip Breathing Ventilation (PLBV) in Advanced COPD

Start date: November 1, 2017
Phase: N/A
Study type: Interventional

Comparison of a conventional non-invasive ventilation to a non-invasive pursed-lip breathing ventilation (PLBV) ventilation in advanced COPD

NCT ID: NCT03292835 Suspended - Clinical trials for Cutaneous Leishmaniases

Complex Cutaneous Leishmaniasis Healing Study in Algeria

LeiClean
Start date: September 1, 2021
Phase:
Study type: Observational [Patient Registry]

This study evaluates the effect of clean wound management and dressing on complex zoonotic cutaneous leishmaniasis caused by L. major in the MENA region (Algeria). The patients will participate in the wound dressing themselves. The objective is to determine the amount of patients that can avoid systemic chemotherapy with pentavalent antimony which is compulsory for patients with complex CL lesions. In Algeria, this requires expensive hospital care because of the eventual toxic side effects of Sb(V).

NCT ID: NCT03291691 Suspended - Anesthesia, Local Clinical Trials

Protective Nerve Stimulation in Regional Anesthesia

ProNerv
Start date: September 20, 2017
Phase:
Study type: Observational

Peripheral nerve blocks can be conducted with ultrasound, electrical nerve stimulation or landmark technique or a combination of this techniques. Whether a regional block should be conducted with a combination of those different possibilities is highly discussed. In this study the investigators want to show the effectiveness of new standard way of combined use of ultrasound and nerve stimulation, they call protective nerve stimulation. According to ethical vote we are conducting an observational study.

NCT ID: NCT03175744 Suspended - Clinical trials for Critical Limb Ischemia

Stellarex DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries

ILLUMENATE-BTK
Start date: May 24, 2017
Phase: N/A
Study type: Interventional

The purpose is to demonstrate the safety and effectiveness of the Stellarex DCB for the treatment of stenosis or occlusions of below-the-knee arteries.

NCT ID: NCT03081897 Suspended - Clinical trials for Head and Neck Cancer

Regional Anaesthesia and Substance P in Head and Neck Cancer

SPRANC
Start date: July 2016
Phase: N/A
Study type: Interventional

In the clinical trial the investigators will observe the impact of regional anesthesia in addition to a general anesthesia on the expression of substance P in patients with unilateral Head or Neck cancer undergoing unilateral Neck Dissection. The investigators will perform an unilateral regional cervical plexus block on the tumor side. The tissue of the tumor side will be analysed by immunohistology, measuring the expression of the Substance P.